Page 3 - Torrent Pharma

Short-term trend in Nifty bearish, stay stock-specific: Vinay Rajani

The trend of midcap and smallcap stocks has been strong and stock specific bullishness is likely to continue

Weak US outlook in near term, higher costs to weigh on Torrent Pharma

While the stock has corrected, valuations leave little room for upside

Torrent Pharma shares tumble 8% post December quarter results

While the outlook for its key geographies is expected to improve over the medium term, the current valuation largely captures the upside, analysts said

Torrent Pharma Q3 net up by 18% to Rs 297 cr even as US revenues dip

India revenues grew 7% to stand at Rs 930 cr. Company's consolidated total revenue from operations fell marginally by under 1% to Rs 2,003 cr in Q3FY21

Torrent Pharma third quarter net profit up 18% at Rs 297 crore

The firm reported an 18.32 per cent rise in its consolidated net profit to Rs 297 crore for the quarter ended in December.

November domestic pharma sales grow just 1% after strong show last month

Oct growth rate was 9.6%; Most big corporates saw volumes drop in November

Torrent Pharma: Cost controls not enough, recovery in key markets crucial

Chronic and sub-chronic therapies, accounting for 77 per cent of India sales, are outperforming the domestic market, say analysts

Sensex surges 377 pts as financial, FMCG stocks rally; Nifty ends at 11,889

All that happened in the markets today

Torrent Pharma Q2 net up 27% despite dip in US and Brazil revenues

Firm's consolidated total revenue for the quarter, however, fell marginally by 0.7% to stand at Rs 2,023 crore

Torrent Pharma Q2 profit up 27% at Rs 310 cr on robust sales, low expenses

The company had posted a net profit of Rs 244 crore for the corresponding period of the previous fiscal, Torrent Pharmaceuticals said in a filing to BSE

Nifty outlook & stock calls by Anand Rathi: Buy TCS, Torrent Pharma

TCS' stock has provided a breakout from a descending triangle pattern on the daily chart

Nifty may resume downtrend if it breaks below 11,350: HDFC Securities

The recent high of 11,794 would continue to act as strong resistance for the Nifty

Cipla tweaks management structure to mobilise second level of executives

Do these changes augur well for the future business growth plans? Analysts think so

Torrent Pharma leaps 10%, nears 52-wk high as Q1 net profit jumps 49% YoY

In terms of markets, while its India revenues grew marginally by 2% on a year-on-year (YoY) basis to Rs 925 crore, up from Rs 907 crore in Q1 of FY20, its US revenues fell by 1% to Rs 373 crore

Torrent Pharma Q1 PBT up 44% to Rs 402 cr, income rises marginally

Domestic and US market revenues more or less flat, 20% drop in Brazilian revenues

Torrent Pharma slips 6% on profit-booking; outlook remains a concern

Unlike peers, Torrent Pharma guided for a relatively moderate outlook across geographies, note analysts at Emkay Global Financial Services.

Torrent Pharma posts Q4FY20 PBT of Rs 293 cr, consolidated revenue up 4.69%

The company saw its total consolidated revenue in Q4FY20 at Rs 1961 crore, up by a marginal 4.69 per cent over Rs 1873 crore in Q4FY19

Market Ahead, May 26: Top factors that could guide markets this week

Corporate results will continue to pour in throughout the week. Investors will first react to HDFC's and other results that were announced over the weekend

MSCI India rebalancing to stoke FPI inflows to the tune of Rs 1,900 cr

The rebalancing is scheduled to take place on May 12 and the changes will become effective from June 1

India growth crucial for Torrent Pharma's health amid steep fall in volume

The country accounts for 44% of overall revenues